Board summary
Key figures
41,852
Registered population
60.8% aged 18–64
19.9%
Aged 65+
ICB 14.9% · England 17.9%
14.5%
In IMD quintile 1
ICB 40.7% · England 21.0%
~5,550
Core20 residents (est.)
Resident basis; registered basis ~6,420 · see page 3
7,622
Hypertension register
+9.31% in 3 yrs · England +5.60%
446
SMI register
12.5% of Wigan (LAD)'s
807
COPD register
Reviews +4.82% in 3 yrs
Forecast to 2030
9,595
Hypertension patients, 2030
+1,973 on today
68.0%
QRISK ≥20% on statins, 2030
+3.43pp over 3 yrs
4.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
COPD and learning disability registers fell.
Over 2023 to 2025, COPD prevalence fell 4.2% (England +2.6%) and learning disability fell 3.5% (England +5.4%), which could reflect unverified coding gaps.
Lipid-lowering therapy trails comparators.
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 60.5%, below England (63.6%), Wigan (LAD) (64.0%) and the ICB (67.0%).
Strong blood pressure and COPD reviews.
Hypertension patients treated to target reach 75.3% (England 70.3%) and COPD annual reviews reach 84.0% (England 76.4%), showing strong register delivery.
Population, age and ethnicity
Older residents make up 19.9% of the PCN, exceeding borough and England benchmarks
Liga Wigan PCN covers 41,852 registered patients. Patients aged 65+ account for 19.9% (8,323 patients), above Wigan (LAD) (18.8%), NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Children aged 0–17 represent 19.3% (8,091 patients), below Wigan (LAD) (20.0%), the ICB (21.8%) and England (19.6%). Gypsy or Irish Traveller residents represent 0.1% (LAD 0.1%, ICB 0.1%, England 0.1%) and Roma residents 0.1% (LAD 0.1%, ICB 0.1%, England 0.2%). Projected list growth of 2.6% to 2030 exceeds Wigan (LAD) (1.1%), the ICB (1.6%) and England (2.3%), though projection methodology is unverified.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Wigan (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wigan LA) | 2,706 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wigan LA) | 1,243 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wigan LA) | 12.3 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is below England overall, yet practice Core20 share spans 16.7 percentage points
The PCN’s Core20 share is 14.5%, below Wigan (LAD) at 29.4%, NHS Greater Manchester Integrated Care Board at 40.7%, and England at 21.0%. Modelled practice shares average a weighted 15.3%, showing a base reconciliation discrepancy against the PCN figure. Practice concentration spans 16.7 pp, from 8.4% at Ssp Health Limited Ashton Medical Centre to 25.1% at Shahbazi Ss. Three practices exceed England, led by Shahbazi Ss (25.1%), while Lowton & Platt Bridge Surgery carries the highest estimated volume at 1,115 Core20 patients (19.6% share).
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
446
SMI register
1.07% recorded prevalence
283
Learning disability register
0.68% recorded prevalence
11
Care homes, 505 beds
In the PCN catchment
10.1%
Provide unpaid care
Wigan (LAD), Census 2021
Recorded severe mental illness includes 446 patients (1.1%, vs Wigan (LAD) 1.0%, ICB 1.1% and England 1.0%), and learning disability includes 283 patients (0.7%, vs Wigan (LAD) 0.7%, ICB 0.6% and England 0.6%). The PCN catchment includes 11 care homes holding 505 beds.
Severe mental illness: physical health checks
Recorded blood pressure checks for patients with severe mental illness reached 90.0% (England 83.4%) and BMI checks reached 92.1% (England 82.1%). Blood pressure check recording rose +3.5 pp over 2023 to 2025 (England +4.4 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,622
Hypertension register
+9.31%
Register growth, 3 yrs
Wigan (LAD) +10.59% · England +5.60%
+3.53pp
BP control, under 80
≤140/90 · +4.45pp aged 80+
+1,973
More patients by 2030
Forecast 9,595 (21.75%)
Hypertension case-finding and control
Recorded hypertension prevalence is 18.2% (7,622 patients), in line with Wigan (LAD) (18.0%), above NHS Greater Manchester Integrated Care Board (14.4%) and England (15.2%). Over 2023 to 2025, prevalence grew +9.3% (+1.6 pp). Blood pressure control is strong: 75.3% of patients are treated to target (England 70.3%) and 72.5% aged under 80 achieve target (England 67.8%). Recent blood pressure checks reach 91.7% (England 90.0%). Practice prevalence ranges from 16.1% at Ssp Health Limited Ashton Medical Centre to 22.3% at High Street Surgery. Blood pressure control above national and ICB averages shows strong management, meaning the PCN should prioritise sustaining recall and treatment protocols.
Lipids and statins
Patients with QRISK ≥ 20% treated with lipid lowering therapy reached 60.5%, trailing England (63.6%), Wigan (LAD) (64.0%) and NHS Greater Manchester Integrated Care Board (67.0%). Similarly, statin treatment for diabetic patients with CVD is 83.2% (England 84.4%). Proactive recall of high-risk patients remains the key clinical priority to close secondary prevention gaps.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 77,156 | £1.90 | £1.94 | £1.86 | £146,596 |
| Cardiovascular (all), 2025 | 116,027 | £4.20 | £3.15 | £3.33 | £487,313 |
For lipid-regulating drugs in 2026, the PCN prescribed 77,156 items at £1.90 per item (£146,596 spend). This was £3,086 more than at England's unit cost (£1.86), but £3,086 less than at NHS Greater Manchester Integrated Care Board's unit cost (£1.94). With unit costs close to benchmarks, expanding treatment reach to untreated high-risk patients takes priority over unit-cost adjustments.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+2.80%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.82%
Asthma prevalence, PCN 3-yr % change
COPD recorded prevalence is 1.9% (807 patients), matching England (1.9%) but below Wigan (LAD) (2.6%). Over 2023 to 2025, COPD prevalence fell 4.2% (England +2.6%, Wigan (LAD) +6.2%), which may reflect detection gaps that clinical audit would test. COPD reviews reach 84.0% (England 76.4%). Asthma prevalence is 7.2% (2,819 patients; England 6.6%), with reviews at 69.7% (England 65.7%), leaving 855 patients without a recorded review. Asthma management items prescribed reached 2,342 per 1,000 population aged 5–19 (England 1,488).
Cancer register and children's immunisation
The cancer register records 1,578 patients (3.8%, matching England 3.8%). In Q1 2025/26, 6-in-1 coverage at 12 months reached 97.8%, and MMR dose 1 at age 5 reached 97.3%, exceeding the 95.0% target. However, age-5 booster coverage was lower: MMR dose 2 reached 90.9% (6.4 pp below dose 1 and 4.1 pp below the 95.0% target), while the 4-in-1 pre-school booster reached 90.0% (5 pp below the 95.0% target).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, across NHS Greater Manchester ICB, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2, matching England (55.3%) but 19.4 percentage points below the 75.0% 2028 ambition. Staging coverage was 70.8% across 16,492 registrations (England 67.0%), meaning unrecorded stage limits precision. Between 2013 and 2022, early-stage share rose +3.1 percentage points from 52.4%, leaving a regional gap of about 2,270 extra early diagnoses annually to achieve 75.0%. PCN cervical screening is 74.7% (England 66.8%), though Golborne Surgery records 60.0%. These wider system figures do not measure PCN performance, but require practices to sustain screening coverage.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, 82.798% of patients met the 28-day faster diagnosis standard, 7.8 pp above the 75.0% standard. However, the trust achieved 76.7801% against the 85.0% 62-day referral to treatment standard (8.2 pp below) and 89.041% on the 96.0% 31-day combined standard (7.0 pp below). Across NHS Greater Manchester Integrated Care Board, 28-day faster diagnosis reached 79.5261% (4.5 pp above), 62-day treatment was 75.7262% (9.3 pp below), and 31-day treatment was 96.4937% (0.5 pp above). Secondary care treatment delays mean PCN clinicians must maintain proactive referral safety-netting.
| Pathways within standard (%) | Wrightington, Wigan and Leigh | Mersey and West Lancashire | North Cheshire and Mersey | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.80 | 72.39 | 80.21 | 79.53 | 79.32 |
| 31-day treatment (96%) | 89.04 | 95.46 | 98.17 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 76.78 | 77.96 | 83.67 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wrightington, Wigan and Leigh | Mersey and West Lancashire | North Cheshire and Mersey | England |
|---|---|---|---|---|
| MRI | 0.49 | 14.04 | 0.53 | 21.40 |
| CT | 7.78 | 13.08 | 2.32 | 9.92 |
| Echocardiography | 24.37 | 34.88 | 28.04 | 28.48 |
| Colonoscopy | 6.10 | 18.04 | 15.98 | 30.83 |
| Gastroscopy | 12.54 | 18.17 | 20.24 | 29.02 |
| All 15 DM01 tests | 14.36 | 21.17 | 6.34 | 23.14 |
| Community services activity | Wigan residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 48,150 | 573,310 |
| Referrals | 13,750 | 94,470 |
| Patients with a contact | 18,695 | 183,535 |
Community services (residents of Wigan), Jun 2026 (provisional). In the Community Services Dataset for Jun 2026 (provisional), adults aged 65+ accounted for 58.5% of community contacts among borough residents (28,190 of 48,150 contacts). These borough-level resident figures describe system activity rather than PCN delivery, highlighting where multidisciplinary community coordination can support older patients.
Practice variation and patient experience
Patient satisfaction spans 27.4 percentage points and vaccination achievement spans 75.5 percentage points
In 2025/26, QOF overall achievement was 88.2% at Shahbazi Ss and 88.2% at High Street Surgery, whereas Slag Lane MC achieved 100.0%, compared with an England level of 92.5%. For QOF vaccination and immunisation-domain achievement, the range between captured practices was 75.5 pp, with Golborne Surgery recording 24.5% and Slag Lane MC recording 100.0%, compared with 55.2% across England.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| High Street | 132 | 24.0 | 81.1% | 71.8% | 89.0% |
| Slag Lane MC | 93 | 14.6 | 73.8% | 62.0% | 84.6% |
| Bryn Street | 115 | 10.5 | 72.3% | 76.9% | 84.5% |
| Lowton & Platt | 97 | 19.6 | 72.0% | 84.2% | 81.0% |
| Shahbazi Ss | 117 | 25.1 | 76.4% | 80.6% | 77.7% |
| Braithwaite Rd | 113 | 9.6 | 58.9% | 85.3% | 75.9% |
| Ssp Health | 94 | 8.4 | 56.1% | 76.5% | 67.9% |
| Golborne Surgery | 83 | 24.6 | 60.6% | 72.3% | 61.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Chronic registers fell while England expanded, contrasting with strong diabetes control gains
Over three years from 2023 to 2025, heart failure functional capacity reviews fell 0.7% (England +8.7%, Wigan (LAD) +3.9%), trailing England's change by 9.4 percentage points. Learning disability prevalence fell 3.5% (England +5.4%, Wigan (LAD) +2.2%), and COPD prevalence fell 4.2% (England +2.6%, Wigan (LAD) +6.2%). In contrast, diabetes HbA1c control without frailty grew +17.1% (England +4.4%), exceeding England by 12.6 percentage points.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Learning disability register
COPD register
Alcohol record (psychosis)
Asthma register
Diabetes HbA1c control
BMI record (SMI)
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wigan (LAD) | Asset | PCN | Wigan (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (505 beds) | n/a | Schools (catchment) | 45 | n/a |
| Children's centres | 4 | 20 | Places of worship | 36 | 164 |
| Libraries | 1 | 10 | Primary schools (LA maintained) | 13 | 68 |
| Primary academies | 4 | 21 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
COPD register case-finding audit
COPD prevalence is 1.9% (807 of 41,852 patients; England 1.9%, Wigan (LAD) 2.6%), falling 4.2% over 2023 to 2025 (England +2.6%), a modelled range of -14 to +269 patients. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 2
Age-five pre-school booster recall
In Q1 2025/26 (cohort 110), age-5 MMR2 is 90.9% (6.4 pp below MMR1 at 97.3%; 4.1 pp below the 95.0% target) and 4-in-1 is 90.0% (5 pp below target). For discussion, practices could audit age-five cohorts for unrecorded second MMR and 4-in-1 doses and offer flexible pre-school catch-up clinic slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Learning disability register validation
Learning disability prevalence is 0.7% (283 patients; Wigan (LAD) 0.7%, England 0.6%), with a 3-year change of -3.5% over 2023 to 2025 versus growth in England (+5.4%) and Wigan (LAD) (+2.2%). Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI check audit (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Sustain blood pressure control (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Access and triage workflow review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · COPD register case-finding audit (p12) | COPD register · COPD: QOF prevalence · Registered population | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 2 · Age-five pre-school booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
